Orion Oyj (OTCMKTS:ORINY) Hits New 12-Month Low at $17.50

Orion Oyj (OTCMKTS:ORINY) reached a new 52-week low during mid-day trading on Monday . The company traded as low as $17.50 and last traded at $17.50, with a volume of 59 shares. The stock had previously closed at $17.50.

Orion Oyj Stock Performance

The business’s 50 day moving average price is $19.34 and its 200-day moving average price is $20.23. The company has a current ratio of 3.10, a quick ratio of 1.59 and a debt-to-equity ratio of 0.21. The company has a market cap of $4.94 billion, a price-to-earnings ratio of 20.83 and a beta of 0.23.

Orion Oyj (OTCMKTS:ORINY) last posted its earnings results on Tuesday, February 13th. The company reported $0.29 earnings per share (EPS) for the quarter. The company had revenue of $345.76 million during the quarter. Orion Oyj had a net margin of 18.21% and a return on equity of 27.75%. On average, equities analysts anticipate that Orion Oyj will post 0.89 EPS for the current fiscal year.

About Orion Oyj

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.